Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques.

[1]  J. Pickard,et al.  Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. , 1999, British journal of clinical pharmacology.

[2]  M. Ferrari,et al.  Coronary side-effect potential of current and prospective antimigraine drugs. , 1998, Circulation.

[3]  J. Pickard,et al.  Differential Distribution of 5Ht1D-and 5HT1B-Immunoreactivity within the Human Trigemino-Cerebrovascular System: Implications for the Discovery of New Antimigraine Drugs , 1997, Cephalalgia : an international journal of headache.

[4]  R Dixon,et al.  The clinical pharmacokinetics of zolmitriptan , 1997, Cephalalgia : an international journal of headache.

[5]  Graham R. Martin.  Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine , 1997, Cephalalgia : an international journal of headache.

[6]  Kirk W. Johnson,et al.  5‐HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs , 1997, Neuroreport.

[7]  J. Heiligers,et al.  Characterization of putative 5‐HT7 receptors mediating tachycardia in the cat , 1997, British journal of pharmacology.

[8]  G. Martin,et al.  Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan) , 1997, British journal of pharmacology.

[9]  G. Martin,et al.  Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. , 1996, Trends in pharmacological sciences.

[10]  M. Ferrari,et al.  311C90, A new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine , 1996, Neurology.

[11]  P. Rolan,et al.  The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. , 1996, British journal of clinical pharmacology.

[12]  M. Ferrari,et al.  Migraine : pharmacology and genetics , 1996 .

[13]  M. Brown,et al.  A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. , 1995, British journal of clinical pharmacology.

[14]  P. Whorwell,et al.  Is chest pain after sumatriptan oesophageal in origin? , 1994, The Lancet.

[15]  H. Posival,et al.  Variable Participation of 5‐HT1‐Like Receptors and 5‐HT2 Receptors in Serotonin‐Induced Contraction of Human Isolated Coronary Arteries: 5‐HT1‐Like Receptors Resemble Cloned 5‐HT1Dβ Receptors , 1994, Circulation.

[16]  P. Goadsby,et al.  Peripheral and Central Trigeminovascular Activation in Cat is Blocked by the Serotonin (5HT)‐I D Receptor Agonist 311C90 , 1994 .

[17]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[18]  G. Plosker,et al.  Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. , 1994, Drugs.

[19]  T. Branchek,et al.  Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. , 1993, The Journal of biological chemistry.

[20]  G. Renzenbrink,et al.  5-HT receptors mediating contractions of the isolated human coronary artery. , 1993, European journal of pharmacology.

[21]  M. Maclean,et al.  Adverse reactions associated with sumatriptan , 1993, The Lancet.

[22]  J. Peacock,et al.  Limitation of pulse oximetry , 1993, The Lancet.

[23]  J. Ottervanger,et al.  Transmural myocardial infarction with sumatriptan , 1993, The Lancet.

[24]  H. Kao,et al.  Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. Hillis,et al.  The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. , 1992, British journal of clinical pharmacology.

[26]  N. Curzen,et al.  Coronary vasospasm induced by subcutaneous sumatriptan. , 1992, BMJ.

[27]  P. Saxena,et al.  5-Hydroxytryptamine: a chameleon in the heart. , 1991, Trends in pharmacological sciences.

[28]  R. Smith,et al.  The safety and tolerability of sumatriptan: an overview. , 1991, European neurology.

[29]  W. Feniuk,et al.  5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. , 1989, European journal of pharmacology.

[30]  M. Perren,et al.  A comparison of 5‐hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists , 1985, British journal of pharmacology.